Not yet recruiting psychedelic research trials
Data as of 10 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.
Not yet recruiting is a registry status. The study is registered but has not opened to participants yet. Status is reported by the study team and can change.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
At a glance
- 65 registered studies are counted on this page.
Which substances
Counts per substance hub. Ketamine is limited to studies classified as psychiatric research, and records about disease-modifying therapy that match the abbreviation DMT are removed.
| Substance hub | Studies |
|---|---|
| Psilocybin | 33 |
| MDMA | 5 |
| LSD | 2 |
| DMT | 1 |
| Ketamine | 24 |
By phase
| Phase | Studies | Share |
|---|---|---|
| Early Phase 1 | 3 | 5% |
| Phase 1 | 17 | 26% |
| Phase 2 | 31 | 48% |
| Phase 3 | 4 | 6% |
| Phase 4 | 2 | 3% |
| Not applicable | 4 | 6% |
| Not reported | 4 | 6% |
Countries
Country is taken from the study's linked research site. 7 of 65 records have no country on file. The top 10 countries are shown.
| Country | Studies | Share |
|---|---|---|
| United States | 35 | 54% |
| Canada | 8 | 12% |
| Switzerland | 3 | 5% |
| France | 2 | 3% |
| Australia | 1 | 2% |
| Brazil | 1 | 2% |
| China | 1 | 2% |
| Egypt | 1 | 2% |
| Spain | 1 | 2% |
| Finland | 1 | 2% |
When studies started
| Start year | Studies |
|---|---|
| 2024 to 2026 | 65 |
Study design
- 61 interventional and 4 observational studies.
- Median planned or actual enrolment is 40 participants (range 3 to 1,010, across 65 records that report it).
Topics named in study titles
A keyword match on registered titles, so one study can appear under more than one topic and a study can be missed. It describes what titles mention, nothing more.
| Topic | Studies |
|---|---|
| Depression and mood | 18 |
| Trauma and PTSD | 7 |
| Other substance use | 7 |
| Cancer and end of life | 4 |
| Pain and headache | 4 |
| Alcohol use | 3 |
| Suicidal thoughts | 3 |
| Anxiety | 1 |
Most recently started studies
The 25 studies with the latest start dates, newest first. The order is not a ranking. Each ID links to its own ClinicalTrials.gov record.
| Registry ID | Title as registered | Status | Phase | Country | Start |
|---|---|---|---|---|---|
| NCT07774702 | Psilocybin for Methamphetamine Use Disorder | Not yet recruiting | Phase 2 | United States | 2027-02 |
| NCT07566104 | Group PACBT for Depression | Not yet recruiting | Phase 2 | United States | 2027-01 |
| NCT07852832 | Effects of Psilocybin on Craving in Nicotine Dependence | Not yet recruiting | Phase 2 | Not reported | 2027-01 |
| NCT07719088 | Psilocybin Effects on Healthy Aging Biomarkers and Purpose in Life | Not yet recruiting | Phase 1 | United States | 2026-12 |
| NCT07768618 | Electrophysiologic Mechanisms of Ketamine Antidepressant Response | Not yet recruiting | Phase 2 | United States | 2026-12 |
| NCT07792538 | Psilocybin-Assisted Psychotherapy for Veterans With PTSD | Not yet recruiting | Phase 2 | Netherlands | 2026-12 |
| NCT07818720 | MLS101 Study in PMDD | Not yet recruiting | Phase 1 | Not reported | 2026-12 |
| NCT07833761 | ADEPT Psilocybin-Assisted Therapy With DBT for Borderline Personality Disorder | Not yet recruiting | Phase 1 | United States | 2026-12 |
| NCT07756736 | Psilocybin Therapy for Methamphetamine Use Disorder and HIV | Not yet recruiting | Phase 2 | United States | 2026-11 |
| NCT07765693 | MDMA-AT for PTSD in Young Adults With Childhood Trauma | Not yet recruiting | Phase 2 | United States | 2026-10 |
| NCT07791901 | MB-PAT for Demoralization in Advanced Cancer ('PAT-MIND') Trial | Not yet recruiting | Phase 2 | Canada | 2026-10 |
| NCT07683988 | Oral and Sublingual Ketamine | Not yet recruiting | Phase 1 | Canada | 2026-10 |
| NCT07704762 | Clinical Trial of MDMA-Assisted Therapy for Military Service Members With Posttraumatic Stress Disorder | Not yet recruiting | Phase 2 | Not reported | 2026-10 |
| NCT07839338 | A Study Comparing Oral Ketamine With Oral Midazolam for the Treatment of Major Depressive Episodes | Not yet recruiting | Phase 3 | India | 2026-10 |
| NCT07820033 | Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer: A Randomized Controlled Trial | Not yet recruiting | Phase 2 | Canada | 2026-09 |
| NCT07433452 | The Effects of Psilocybin in Healthy Volunteers: Psychological, Biochemical and Electrophysiological Biomarkers. | Not yet recruiting | Phase 1 | Not reported | 2026-09 |
| NCT07693257 | Neural Effects of Intravenous N,N-dimethyltryptamine (DMT) | Not yet recruiting | Phase 1 | United States | 2026-09 |
| NCT07801703 | Behavioural Activation Therapy and Ketamine for Treatment-Resistant Depression | Not yet recruiting | Phase 2 | Canada | 2026-09 |
| NCT07824973 | Ketamine Treatment for Treatment-Resistant Depression - the Role of Framing | Not yet recruiting | Not applicable | Sweden | 2026-09 |
| NCT07693153 | The Effects of Psilocybin on Social Connectedness | Not yet recruiting | Phase 1 | United States | 2026-08 |
| NCT07745569 | Assessing of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies | Not yet recruiting | Phase 2 | United States | 2026-08 |
| NCT07760740 | The Effect of Intraoperative Infusion of Esketamine on Cholestatic Pruritus in Patients Undergoing Hepatobiliary Surgery | Not yet recruiting | Not applicable | China | 2026-08 |
| NCT06885996 | Psilocybin-assisted Therapy for Post-Traumatic Stress Disorder in Survivors of Intimate Partner Violence | Not yet recruiting | Phase 2 | Canada | 2026-08 |
| NCT07499583 | Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use Disorder | Not yet recruiting | Phase 1 | United States | 2026-08 |
| NCT07614581 | Intra-Sessional Autonomic Arc Detection in Ketamine-Assisted Therapy for PTSD: A Signal Characterisation Pilot Study | Not yet recruiting | Not reported | Canada | 2026-07 |
Other substance hubs
Psilocybin | MDMA | LSD | DMT | 5-MeO-DMT | Ayahuasca | Ketamine | Ibogaine
Registry status hubs
Recruiting | Active, not recruiting | Enrolling by invitation | Completed | Terminated | Suspended | Withdrawn
Phase hubs
Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Phase not applicable